Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C2L-OCT-01 PR vs Sandostatin LAR in Acromegaly
NCT00616551Phase 3Completed
- Sponsor
- Ambrilia Biopharma Inc.
- Start
- Apr 2007
- Primary completion
- Feb 2008
- Modality
- Peptides
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial of octreotide in acromegaly (2 arms), sponsored by Ambrilia Biopharma Inc. Primary endpoint: Mean serum concentrations of insulin-like growth factor-1 (IGF-1) and growth hormone (GH) at Day 84. Started Apr 2007; status: completed.
02
Drugs
octreotide
03
Conditions
acromegaly
Beyond the preview
Go deeper on NCT00616551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00616551.